Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (ADPT) from its SEC filings: 2025 revenue $277.0 million (+55% vs the year before), net margin -22%, free cash flow -$48.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $277.0 million |
| Revenue growth | +55% |
| Net income | -$59.5 million |
| Net margin | -21.5% |
| Free cash flow | -$48.9 million |
| Diluted EPS | $-0.39 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +22% |
| Cash | $169.9 million |
| Long-term debt | $0 |
| Share count, 1 year | +5% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.